Novel taxanes

Anti-Cancer Drugs

Volumn 25, Issue 5, 2014, Pages 593-598

  Muggia, Franco ^a   Kudlowitz, David ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

drug development; Mitotic inhibitors; Taxanes

Indexed keywords

BRENTUXIMAB VEDOTIN; CABAZITAXEL; DOCETAXEL; IMMUNOTOXIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; POLYMER; TAXANE DERIVATIVE; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; TAXOID;

ALOPECIA; ANEMIA; ARTHRALGIA; ASTHENIA; BONE MARROW TOXICITY; BREAST CANCER; CANCER RESISTANCE; CHILL; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SPECIFICITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HODGKIN DISEASE; HUMAN; LEUKOPENIA; METASTATIC BREAST CANCER; MICELLE; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; ONCOLOGIST; OVARY CANCER; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; STOMACH CANCER; TRIPLE NEGATIVE BREAST CANCER; VOMITING; DRUG COMBINATION; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTOXINS; NEOPLASMS; TAXOIDS;

EID: 84908391151     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000053     Document Type: Review

References (33)

1. Campos SM, Dizon DS. Antimitotic inhibitors. Hematol Oncol Clin North Am 2012; 26:607-628.
2. Weinberg RA, Hanahan D. The hallmarks of cancer. Cell 2000; 100:57-70.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674.
4. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376:1147-1154.
5. Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study. Eur J Cancer 2011; 47:1037-1045.
6. Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h IV infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547-1552.
7. Semlond D, Sidhu SS, Bissery M-C, Vringnaud P. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Cancer Chemother Pharmacol 2013; 72:515-528.
8. Singer JW, Baker B, De Vries P, Kumar A, Shaffer S, Vawter E, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: Characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 2003; 519:81-99.
9. O'Brien MER, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, et al. Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapynaïve advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 728-734.
10. Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol 2008; 3:623-630.
11. Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study. Gynecol Oncol 2008; 111:455-460.
12. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101:1401-1413.
13. Lohr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: A randomized controlled phase II trial. Ann Oncol 2012; 23:1214-1222.
14. Awada A, Bondarenko IN, Tarasova O, Bonneterre J, Nowara E, Ferrero JM, et al. Results of the first randomized phase II study of cationic liposomal paclitaxel (EndoTag-1t) targeting tumor endothelial cells in advanced triple negative breast cancer 2010; Milan; presented at the ESMO Congress. Available at: http://www.medigene.com/sites/default/files/downloads/101012-endotagpresentation-esmo-2010.pdf. [Accessed 1 September 2013].
15. Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M. Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004; 110:117-124.
16. Mita AC, Denis LJ, Rowinsky EK, DeBono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723-730.
17. Cisternino S, Bourasset F, Archimbaud Y, Sémiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 2003; 138:1367-1375.
18. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J Control Release 2001; 72:191-202.
19. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of genexol-PM, a novel cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007; 18:2009-2014.
20. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim S-B, et al. Multicenter phase II trial of genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 108:241-250.
21. Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, et al. A multi-center, late phase II clinical trial of genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 2004; 12:1059-1064.
22. Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, et al. TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther 2012; 11:1959-1967.
23. Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001; 7:3229-3238.
24. Payne M, Ellis P, Dunlop D, Ranson M, Danson S, Schacter L, Talbot D. DHA-paclitaxel (taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: Report of a phase II open-label multicenter trial. J Thorac Oncol 2006; 1:984-990.
25. Bissery M-C, Vrignaud P, Combeau C, Riou J-F, Bouchard H, Commercon A, Lavelle F. Preclinical evaluation of XRP9881A, a new taxoid. Experimental and molecular therapeutics 52: Tublin-targeted agents. Proc Amer Assoc Cancer Res 2004; 45:AACR meeting abstracts online. Available at: http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/1253-a. [Accessed 1 September 2013].
26. Zatloukal P, Gervais R, Vansteenkiste J, Bosquee L, Sessa C, Brain E, et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol 2008; 3:894-901.
27. Dieras V, Limentani S, Romieu G, Tubiana-Hulin M, Lortholary A, Kaufman P, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxanebased therapy. Ann Oncol 2008; 19:1255-1260.
28. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A. DJ-927 a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 2003; 94:459-466.
29. Baas P, Szczesna A, Albert I, Milanowski J, Juhász E, Sztancsik Z, et al. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. J Thorac Oncol 2008; 3:745-750.
30. Rose WC, Fairchild C, Lee FYF. Preclinical antitumor activity of two novel taxanes. Cancer Chemother Pharmacol 2001; 47:97-105.
31. Camps C, Felip E, Sanchez JM, Massuti B, Artal A, Paz-Ares L, et al.PhaseII trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 2005; 16:597-601.
32. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783-1791.
33. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-2189.